NCT04854837

Safety of Remdesivir Treatment in COVID-19 Patients Requiring Hemodialysis

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 45 (actual)
• Sponsor: Semmelweis University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The FDA approved the antiviral drug remdesivir for use in adults for the treatment of COVID-19 requiring hospitalization. There are only limited data about the safety of the drug in hemodialysed patents. Chronic kidney disease is a risk factor in COVID-19 for developing severe disease. The aim of our investigation is to observe the safety of remdesivir among hemodialysed patients requiring hospitalization for COVID-19. We are going to compare two group's data: 1. Hemodialysed COVID-19 patients requiring hospitalization because of pneumonia and need of oxygen supplementation, and admitted after 12/Apr/2021 - these patients received remdesivir. 2. Hemodialysed COVID-19 patients requiring hospitalization because of pneumonia and need of oxygen supplementation, and admitted before 12/Apr/2021 - these patients did not receive remdesivir.

Conditions

• Covid19
• End Stage Renal Failure on Dialysis

Interventions

Type	Name	Description
DRUG	Remdesivir	Remdesivir treatment

Timeline

• Start date: 2021-04-12
• Primary completion: 2022-09-30
• Completion: 2022-09-30
• First posted: 2021-04-22
• Last updated: 2022-11-09

Locations

1 site across 1 country: Hungary